Cantargia AB (CHIX:CANTAS) PE Ratio without NRI: 6.42 (As of Jun. 29, 2026) — Near Median


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB PE Ratio without NRI?

Cantargia AB CHIX:CANTAS 37 PE Ratio without NRI is 6.42 as of Jun. 29, 2026, which is 2% below its 10-year median of 6.54. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 268 Biotechnology companies, Cantargia AB ranks better than 93.66% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-29), Cantargia AB's share price is kr4.174. Cantargia AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.65. Therefore, Cantargia AB's PE Ratio without NRI for today is 6.42.

During the past 13 years, Cantargia AB's highest PE Ratio without NRI was 10.51. The lowest was 3.26. And the median was 6.54.

Cantargia AB's EPS without NRI for the three months ended in Mar. 2026 was kr-0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.65.

As of today (2026-06-29), Cantargia AB's share price is kr4.174. Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.65. Therefore, Cantargia AB's PE Ratio (TTM) for today is 6.42.

Good Sign:

Cantargia AB stock PE Ratio (=3.3) is close to 1-year low of 3.26.

During the past years, Cantargia AB's highest PE Ratio (TTM) was 10.51. The lowest was 3.26. And the median was 6.54.

Cantargia AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.65.

Cantargia AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.65.


Cantargia AB  (CHIX:CANTAs) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Cantargia AB PE Ratio without NRI Related Terms


Cantargia AB PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Cantargia AB's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB PE Ratio without NRI Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 7.22

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 5.01 7.22 6.28

CHIX:CANTAS vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, Cantargia AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cantargia AB's PE Ratio without NRI falls into.


CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Cantargia AB's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=4.174/0.650
=6.42

Cantargia AB's Share Price of today is kr4.174.
Cantargia AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.65.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 6.42 mean?
Cantargia AB (CHIX:CANTAS) has a PE Ratio without NRI of 6.42 as of Jun. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Cantargia AB and its competitors. This is near median its historical median of 6.54. Over the past decade, Cantargia AB's PE Ratio without NRI has ranged from 3.26 to 10.51. According to the industry distribution chart, Cantargia AB ranks #17 out of 268 companies in the Biotechnology industry, placing it in the top 6.3%.
Is Cantargia AB's PE Ratio without NRI too high?
Cantargia AB's current PE Ratio without NRI of 6.42 is near median its 10-year median of 6.54. Over the past 10 years, this metric has ranged from a low of 3.26 to a high of 10.51. The Biotechnology industry median PE Ratio without NRI is 25.06. Cantargia AB's value of 6.42 is 74.4% below this industry median. Based on the distribution chart, Cantargia AB ranks #17 out of 268 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #17 out of 268 companies for PE Ratio without NRI. This places Cantargia AB in the top 6% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 25.06. Cantargia AB's value of 6.42 is 74.4% below this benchmark. Historically, Cantargia AB's own PE Ratio without NRI has ranged from 3.26 to 10.51 over the past decade. While the company's 10-year median is 6.54 vs. the industry median of 25.06, Cantargia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.06, based on 268 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current PE Ratio without NRI of 6.42 is 74.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current PE Ratio without NRI is 6.42, which is near median its own 10-year median of 6.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current PE Ratio without NRI of 6.42. The current PE Ratio without NRI is 6.42, which is near median its 10-year median of 6.54 and 74.4% below the Biotechnology industry median of 25.06. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current PE Ratio without NRI is 6.42 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price